Carcinoid
Back to Oncology/Cancer Clinical Trials Main PageCPMC Cancer Services
| Principal Investigator/Contact Information | Protocol Title | Patient Population | Recruitment Period |
| Principal Investigator: CPMC Oncologists Contact: Brenda Eng 415-600-1775 | Phase III Trial Prospective Randomized Comparison of Depot Octerotide Plus Interferon Alpha Versus Deopot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients. SWOG S0518 Visit this study on ClinicalTrials.gov. | Subjects with unresectable metastatic or locally advanced, low- or intermediate-grade neuroendocrine carcinoma | Open |
updated 11/13/09
Back to top